IND Submission: How to Qualify Your Cell Therapy Starting Material Supplier

IND submission requires sponsors to demonstrate that their cell therapy starting material comes from a qualified supplier operating under an appropriate regulatory framework. This sounds straightforward until you sit down to write the supplier qualification section of the CMC and realize that most guidance documents describe the endpoint without explaining the process for getting there.

This guide covers what FDA expects in starting material supplier qualification for a cell therapy IND, the regulatory frameworks that apply (and when each applies), the single most expensive mistake sponsors make in transitioning from research to GMP starting material, and a 25-point supplier audit checklist you can use in the qualification process.

What FDA Expects for Starting Material Supplier Qualification

FDA’s expectations for cell therapy starting material documentation in an IND submission are found across several guidance documents, including the 2008 Guidance for Industry on Cellular and Gene Therapy Products and the 21 CFR 1271 regulations. The core expectations are:

• The supplier of HCT/P starting material must be registered with FDA as an HCT/P establishment under 21 CFR 1271
• The supplier’s processing operations must comply with Good Tissue Practice regulations (21 CFR 1271 Subpart D) for research-phase materials, and with cGMP requirements for Phase III and commercial manufacturing
• The IND CMC section must describe the starting material source, collection method, processing steps, and specifications, along with documentation that the supplier meets applicable quality standards
• Lot release testing for starting material should be documented in the IND, with acceptance criteria that have been established and validated
• Chain-of-identity documentation must trace each lot of starting material from donor through processing through the manufactured cell therapy product

The depth of required documentation scales with the phase of the IND. Phase I INDs have more flexibility in the CMC section than Phase III applications. But the foundational supplier qualification documentation — registration, GTP compliance, lot release criteria — is expected at every phase.

GTP vs. cGMP: Understanding the Regulatory Boundary

One of the most common points of confusion in cell therapy starting material sourcing is the line between Good Tissue Practice (GTP) and current Good Manufacturing Practice (cGMP). These are different regulatory frameworks with different documentation, validation, and oversight requirements, and the appropriate standard depends on the phase of the program.

Good Tissue Practice (21 CFR 1271 Subpart D) applies to establishments that process HCT/Ps. GTP covers facilities and environmental controls, equipment maintenance and calibration, SOPs and change control, donor eligibility determination, processing procedures, labeling, storage, and adverse reaction reporting. GTP is the baseline regulatory standard for HCT/P processing and applies to leukopak and PBMC processing suppliers operating in the research and early clinical phases.

Current Good Manufacturing Practice (21 CFR 211 / 21 CFR 600-680) applies to the manufacture of drug products and biological products. As a cell therapy program advances toward Phase III and commercial manufacturing, FDA expects that manufacturing steps — including starting material processing for some programs — will be performed under cGMP. The transition point varies by program and product type, but the general expectation is that Phase III pivotal trials use cGMP-manufactured investigational products.

The practical implication: a starting material supplier qualified for Phase I/II under GTP may not be qualified for Phase III under cGMP without additional qualification work. If your Phase I supplier cannot demonstrate cGMP capability for Phase III, you face a supplier qualification exercise during one of the most time-sensitive phases of your program. Selecting a supplier early that can operate under both frameworks eliminates this constraint.

The Supplier Swap Problem: The Most Expensive Mistake in Cell Therapy CMC

The most expensive mistake in cell therapy CMC is switching starting material suppliers between the research phase and the GMP phase without a comparability study to demonstrate that material from the new supplier is equivalent to material used in the research that supported the IND.

The scenario plays out consistently across cell therapy programs: research is conducted using research-use (RUO) starting material from a supplier with good product availability and a fast procurement process. At IND filing, the program needs GMP-grade starting material, and either the RUO supplier doesn’t have a GMP program, or the GMP program wasn’t qualified as part of the original supplier selection. The program switches to a different GMP supplier.

FDA’s expectation at IND is that the sponsor can characterize the starting material and demonstrate consistency between lots. If the IND is built on preclinical and early clinical data generated with material from Supplier A, and the IND CMC proposes to use starting material from Supplier B, the comparability burden is real. The sponsor must demonstrate that the manufacturing process produces an equivalent cell therapy product from Supplier B’s starting material as it did from Supplier A’s. This typically requires additional manufacturing runs, release testing comparison, and in some cases functional comparability data.

The prevention is straightforward: qualify a starting material supplier who can provide both RUO and GMP-grade material from the same donor pool, under the same processing infrastructure, before preclinical work begins. Same-donor continuity from research phase through GMP eliminates the comparability question entirely. The starting material used to characterize the process is the same starting material used in clinical manufacturing.

What to Look for in Supplier Qualification: The 25-Point Audit Checklist

Use this checklist when conducting a supplier qualification audit for cell therapy starting material. The criteria are organized across five categories: regulatory standing, quality management system, product specifications, supply chain reliability, and program support capabilities.

Category 1: Regulatory Standing

1. FDA HCT/P establishment registration. Confirm the supplier holds current FDA establishment registration for each physical processing facility. Verify independently at the FDA’s HCT/P establishment registration database (21 CFR 1271.21). Registration numbers for all processing locations should be provided and verified, not just registration for the parent organization.
2. GTP compliance documentation. Request documentation of the supplier’s GTP compliance program, including their most recent internal audit findings and corrective actions. A supplier that cannot produce internal audit records is not operating a functional GTP QMS.
3. Inspection history. Request FDA inspection history for each processing facility. 483 observation letters and Warning Letters are public record. Review any prior inspection findings and the supplier’s responses to assess the depth and seriousness of identified deviations.
4. cGMP capability (for Phase III and commercial supply). If your program will require cGMP starting material for Phase III, confirm whether the supplier’s processing facilities are cGMP-qualified or whether cGMP qualification is planned and on what timeline.
5. AABB accreditation or equivalent. AABB (formerly American Association of Blood Banks) accreditation for cellular therapy products is an independent third-party quality indicator. Not all suppliers are AABB-accredited, but accreditation history or voluntary compliance with AABB standards is a positive quality signal.

Category 2: Quality Management System

6. SOP documentation and version control. Request the SOP index covering apheresis collection, product receipt, processing, release testing, labeling, storage, and shipping. Confirm that SOPs are version-controlled with documented change control processes.
7. Deviation management. Ask for the deviation management procedure and examples of completed deviation reports with root cause analysis and corrective actions. A supplier who has never had a documented deviation is not running a functional quality system — deviations happen, and the question is whether they are captured, investigated, and corrected.
8. Release testing and specification documentation. Request the full release testing panel for the specific product you are purchasing (leukopak, processed PBMC, cryopreserved PBMC). Confirm that acceptance criteria are documented and that the supplier has historical data demonstrating consistency against those criteria.
9. Lot retention and stability. Confirm whether the supplier retains representative samples from each lot for stability testing. For programs building comparability datasets, access to retain samples from earlier lots is valuable.
10. Supplier qualification for reagents and consumables. Ask how the supplier qualifies their own reagents and consumables (density gradient media, anticoagulants, cryoprotectants). A supplier whose input materials are unqualified introduces quality variability that is invisible in the final product specifications.
11. Quality oversight structure for multi-site operations. If the supplier operates multiple processing facilities, confirm whether there is a central quality authority with oversight of all locations or whether quality decisions are made locally. For multi-site suppliers, a single QMS with centralized authority is the standard you should require.

Category 3: Product Specifications

12. PBMC viability documentation. Request average viability data across recent lots, not just the published minimum specification. A supplier’s floor spec tells you where they release product; the lot-to-lot average tells you where typical performance lands.
13. Granulocyte and platelet contamination. Request documented granulocyte content (% CD15+ or % CD66b+) and platelet contamination data across recent lots. High granulocyte content (>5%) confounds T cell and NK cell functional assays. High platelet contamination affects cytokine and activation assays.
14. CD4/CD8 ratio documentation. For programs where starting material CD4:CD8 ratio is a manufacturing input parameter (particularly CAR-T), confirm that the supplier measures and documents this metric on each lot. Published research has identified starting material CD4:CD8 ratio below 1:3 as a predictor of CAR-T manufacturing failure.
15. Total nucleated cell count and PBMC yield. Confirm how yield is measured and reported. Total nucleated cells in the leukopak versus processed PBMC yield are different numbers, and a supplier quoting the former when you need the latter is comparing apples and oranges.
16. Post-thaw specifications for cryopreserved product. If you are purchasing cryopreserved material, request post-thaw viability, post-thaw recovery, and post-thaw functional data (e.g., response to PHA stimulation) from recent lots. Recovery and functional capacity post-thaw are the specifications that matter for most downstream applications, not pre-freeze viability.
17. HLA typing methodology and reporting. Confirm the resolution level of HLA typing (low, intermediate, or high resolution) and which loci are typed as standard (HLA-A, B, C, DR, DQ minimum for cell therapy applications). Request the format of HLA data delivery.

Category 4: Supply Chain Reliability

18. Collection deliverability rate. Ask for documented collection success rates across the most recent 12-month period. A supplier claiming high deliverability without supporting data is making a marketing claim, not a quality claim.
19. Cold chain documentation. Request the cold chain management procedure covering temperature monitoring from processing through final delivery. For fresh leukapheresis product, time-temperature records for each shipment should be available on request.
20. Chain-of-identity documentation. Request an example of chain-of-identity documentation from a recent lot, from donor consent through processed product release. This is the documentation that will appear in your IND CMC section and that FDA will review.
21. Donor recruitment and eligibility screening. Confirm that the supplier’s donor eligibility determination process meets or exceeds 21 CFR 1271.75 requirements. For allogeneic programs, ask about communicable disease testing panels (HIV, HBV, HCV, HTLV, syphilis, CMV at minimum) and whether residual disease risk is disclosed per lot.
22. Same-donor repeat collection capability. Confirm whether the supplier can support repeat collections from the same donor across different time points or phases of a program. Same-donor continuity from RUO to GMP phases is the primary risk mitigation for the supplier swap comparability problem described above.

Category 5: Program Support Capabilities

23. Technical support for IND CMC preparation. Ask whether the supplier has experience providing supplier documentation packages for IND submissions and whether they can provide a standard documentation package that includes regulatory standing, QMS summary, product specifications, and representative COAs formatted for CMC inclusion.
24. Custom specification accommodation. Confirm whether the supplier can meet custom specifications if your program requires parameters outside their standard release criteria (e.g., specific CD4:CD8 ratio ranges, maximum monocyte contamination thresholds, specific HLA allele requirements for NK programs).
25. CTDMO integration capability. If your program will transition from starting material procurement to contracted manufacturing, confirm whether the supplier has CTDMO capability that allows the starting material qualification and manufacturing relationship to remain under one quality system, or whether you will need to qualify a separate CTDMO and manage the supplier handoff.

OrganaBio’s Documentation Package for IND Qualification

OrganaBio’s CTDMO team has prepared cell therapy starting material suppliers for IND qualification audits across multiple program types. The standard documentation package we provide for sponsor qualification activities includes:

• FDA HCT/P establishment registration certificates for each Cell Processing Center
• GTP compliance summary and SOP index
• Representative COAs from recent leukopak and processed PBMC lots
• Lot-to-lot viability, yield, and cell quality data across the trailing 12 months
• Chain-of-identity documentation template formatted for IND CMC inclusion
• Donor eligibility determination summary per 21 CFR 1271.75
• Technical description of the 30-minute receipt-to-processing standard and its role in product quality consistency

For programs that need same-donor continuity from research-phase characterization through GMP manufacturing, OrganaBio’s donor program enables this by design. The same donor pool that supports RUO starting material procurement is the same pool from which GMP-qualified collections are drawn — under the same quality system, at the same Cell Processing Centers, with the same processing personnel and SOPs.

Getting Started on Supplier Qualification

Starting the supplier qualification process before it is urgently needed gives sponsors the most flexibility. IND submission timelines are rarely as padded as program managers expect, and supplier qualification that should take four weeks can consume twelve when documentation requests encounter supplier backlog or when audit findings require corrective action before qualification can close.

If you are planning a cell therapy IND and need to qualify a starting material supplier, or if you are reviewing your current supplier qualification documentation and want to identify gaps before FDA does, OrganaBio’s CTDMO team can support the process. Contact us to request a documentation package and discuss your program’s timeline.

Frequently Asked Questions